Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis
Open Access
- 4 February 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2), e88390
- https://doi.org/10.1371/journal.pone.0088390
Abstract
Treatment and prevention of thrombotic complications is frequently required in patients with cirrhosis. However anticoagulant therapy is often withheld from these patients, because of the perceived bleeding diathesis. As a result of the limited clinical experience, the anticoagulant of choice for the various indications is still not known. We evaluated the in vitro effect of clinically approved anticoagulant drugs in plasma from patients with cirrhosis. Thirty patients with cirrhosis and thirty healthy controls were studied. Thrombin generation assays were performed before and after addition of unfractionated heparin, low molecular weight heparin, fondaparinux, dabigatran, and rivaroxaban, to estimate anticoagulant potencies of these drugs. Addition of dabigatran led to a much more pronounced reduction in endogenous thrombin potential in patients compared to controls (72.6% reduction in patients vs. 12.8% reduction in controls, P<0.0001). The enhanced effect of dabigatran was proportional to the severity of disease. In contrast, only a slightly increased anticoagulant response to heparin and low molecular weight heparin and even a reduced response to fondaparinux and rivaroxaban was observed in plasma from cirrhotic patients as compared to control plasma. The anticoagulant potency of clinically approved drugs differs substantially between patients with cirrhosis and healthy individuals. Whereas dabigatran and, to a lesser extent, heparin and low molecular weight heparin are more potent in plasma from patients with cirrhosis, fondaparinux and rivaroxaban showed a decreased anticoagulant effect. These results may imply that in addition to dose adjustments based on altered pharmacokinetics, drug-specific dose adjustments based on altered anticoagulant potency may be required in patients with cirrhosis.Keywords
This publication has 24 references indexed in Scilit:
- The Coagulopathy of Chronic Liver DiseaseThe New England Journal of Medicine, 2011
- Enhanced thrombin generation in patients with cirrhosis‐induced coagulopathyJournal of Thrombosis and Haemostasis, 2010
- Hemostasis and thrombosis in patients with liver disease: The ups and downsJournal of Hepatology, 2010
- Rebalanced hemostasis in patients with liver disease: evidence and clinical consequencesBlood, 2010
- Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory methodHepatology, 2010
- Comparative study of coagulation and thrombin generation in the portal and jugular plasma of patients with cirrhosisThrombosis and Haemostasis, 2010
- Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation testsJournal of Hepatology, 2009
- An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With CirrhosisGastroenterology, 2009
- Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation testsHepatology, 2005
- Haemostatic abnormalities in patients with liver diseaseJournal of Hepatology, 2002